Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers from the Department of Experimental Psychology at the University of Oxford have developed a new mental health treatment programme to provide frontline healthcare workers with 1-to-1 support, including fast-track access to PTSD or depression treatment. This evidence-based programme, called SHAPE Recovery, builds on an outreach programme shown to reduce rates of PTSD and depression.

Healthcare professional wearing a mask © eldar nurkovic / Shutterstock

SHAPE Recovery is working with 3,300 frontline healthcare workers across England and has now been invited to work with 8,000 London Ambulance employees and staff from associated partner organisations.

Around the world, frontline healthcare workers, such as intensive care doctors, nurses, support staff and paramedics, are risking their lives daily to stem the tide of the COVID-19 pandemic. They are at an increased risk of developing mental health problems, such as a severe stress reaction called post-traumatic stress disorder (PTSD) as well as depression, sleep problems and anxiety. Although many hospitals offer well-being initiatives, there is little evidence to support their effectiveness and they require staff to come forward for help.

Read the full article (University of Oxford website)

Similar stories

General anaesthesia should be available for dying patients - medical and ethical experts

General Research

General anaesthesia should be more widely available for patients at the end of their lives, according to Oxford experts in ethics and anaesthesia, according to a paper published by Anaesthesia (a journal of the Association of Anaesthetists).

Human challenge trial launches to study immune response to COVID-19

Clinical Trials Coronavirus COVID-19 General

Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.